This study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a "study drug", and together be called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aims of this study are to see how safe and tolerable BNT116 is in combination with cemiplimab and to see how effective BNT116 in combination with cemiplimab is compared to cemiplimab by itself at treating cancer. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the drug less effective or could lead to side effects)
Advanced Non-Small Cell Lung Cancer
This study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a "study drug", and together be called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aims of this study are to see how safe and tolerable BNT116 is in combination with cemiplimab and to see how effective BNT116 in combination with cemiplimab is compared to cemiplimab by itself at treating cancer. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the drug less effective or could lead to side effects)
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
-
The Oncology Institute of Hope and Innovation, Los Angeles, California, United States, 90033
University of California Irvine, Orange, California, United States, 92697
UCLA Medical Center, Santa Monica, California, United States, 90095
Norton Cancer Institute, Downtown, Louisville, Kentucky, United States, 40202
Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States, 02215
San Juan Oncology Associates, Farmington, New Mexico, United States, 87401
Weill Cornell Medical College, New York, New York, United States, 10065
Oncology Specialists of Charlotte Pa, Charlotte, North Carolina, United States, 28204
FirstHealth of the Carolinas, Inc., Pinehurst, North Carolina, United States, 28374
Millenium Research & Clinical Development, Houston, Texas, United States, 77090
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Regeneron Pharmaceuticals,
Clinical Trial Management, STUDY_DIRECTOR, Regeneron Pharmaceuticals
2027-06-07